TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SODIUM PHENYLACETATE AND SODIUM BENZOATE

SODIUM BENZOATE
Approved 2016-02-24
5
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-02-24
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

SODIUM PHENYLACETATE AND SODIUM BENZOATE Approval History

Loading approval history...

What SODIUM PHENYLACETATE AND SODIUM BENZOATE Treats

3 indications

SODIUM PHENYLACETATE AND SODIUM BENZOATE is approved for 3 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hyperammonemia
  • Encephalopathy
  • Urea Cycle Disorder
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SODIUM PHENYLACETATE AND SODIUM BENZOATE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementatio...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.